Videos

Karl M. Kilgore, PhD, discusses the role of chimeric antigen receptor T-cell therapy as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma and where this option might fit into the landscape in the future.

Matthew Krebs, MBChB, PhD, explains the rationale for a phase II study of bemcentinib, a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced non–small cell lung cancer, which he presented at the 2019 Society for Immunotherapy of Cancer Annual Meeting.

A 56-Year-Old Female With Recurrent Ovarian Cancer

Jason Luke, MD, FACP, discusses promising clinical research around intratumoral immunotherapy.

TKI in Poor-Risk Advanced Renal Cell Carcinoma

Courtney D. DiNardo, MD, MSCE, explains the rationale for the phase II AG221-AML-005 trial.

Raja E. Abdulnour, MD, discusses modern management strategies for pneumonitis induced by treatment with immune checkpoint inhibitors in patients with kidney cancer.

Jason Williams, MD, the director of Interventional Oncology and Immunotherapy oncologist at the Williams Cancer Institute, discusses a study in which an immunotherapy combination was administered intratumorally to patients with liver metastases linked to breast cancer, which he presented in a poster at the 2019 Society of Immunotherapy of Cancer Annual Meeting.

Peter R. Galle, MD, discusses the findings that came from the phase III IMbrave 150 clinical trial, which evaluated the combination of atezolizumab plus bevacizumab versus the standard of care, sorafenib, as frontline treatment of patients with unresectable hepatocellular carcinoma.

Mira Hellmann, MD, discusses how the use of PARP inhibitors as treatment of patients with gynecologic cancers has evolved since they were first introduced into the treatment landscape up to studies evaluating these therapies today in a variety of patient populations, particularly in patients with ovarian cancer.

Nasser H. Hanna, MD, discusses the key takeaways on the current role of consolidation immunotherapy in patients with lung cancer, which has become standard in this setting. He highlights questions that still need to be addressed in this space.

Vincent Herrin, MD - University of Mississippi Medical Center Jackson, Mississippi

Arati Desai, MD, explains how the results from the phase III STELLAR trial will enhance knowledge of anaplastic astrocytoma.

A. Oliver Sartor, MD, discusses the current treatment options for patients with nonmetastatic castration-resistant prostate cancer (CRPC) and what physicians should consider when selecting treatment for their patients.

Scott Kopetz, MD, PhD, discusses the results of the phase III BEACON CRC study, which was presented at the 2020 Gastrointestinal Cancers Symposium.

Rashmi K. Murthy, MD, discusses the pivotal HER2CLIMB trial, which evaluated the addition of tucatinib to trastuzumab plus capecitabine in patients with HER2-positive metastatic breast cancer.

Ryan J. Sullivan, MD, compares the toxicity profiles of BRAF-targeted therapy and immunotherapy used for the treatment of patients with melanoma.

Jasmeet C. Singh, MD, discusses the future of the treatment landscape for HER2-positive breast cancer following positive new research presented at the 2019 San Antonio Breast Cancer Symposium.